Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Age- and sex-related variations in vocal-tract morphology and voice acoustics during adolescence.

Markova D, Richer L, Pangelinan M, Schwartz DH, Leonard G, Perron M, Pike GB, Veillette S, Chakravarty MM, Pausova Z, Paus T.

Horm Behav. 2016 May;81:84-96. doi: 10.1016/j.yhbeh.2016.03.001. Epub 2016 Apr 8.

PMID:
27062936
2.

Effect of Early Adversity and Childhood Internalizing Symptoms on Brain Structure in Young Men.

Jensen SK, Dickie EW, Schwartz DH, Evans CJ, Dumontheil I, Paus T, Barker ED.

JAMA Pediatr. 2015 Oct;169(10):938-46. doi: 10.1001/jamapediatrics.2015.1486.

3.

Policy and the transparency of values in science.

Schwartz DH.

Environ Health Perspect. 2014 Nov;122(11):A291. doi: 10.1289/ehp.1408936. No abstract available.

4.

Adiposity is associated with structural properties of the adolescent brain.

Schwartz DH, Dickie E, Pangelinan MM, Leonard G, Perron M, Pike GB, Richer L, Veillette S, Pausova Z, Paus T.

Neuroimage. 2014 Dec;103:192-201. doi: 10.1016/j.neuroimage.2014.09.030. Epub 2014 Sep 26.

PMID:
25255944
5.

Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.

Iyengar S, Zhan C, Lu J, Korngold R, Schwartz DH.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1104-11. doi: 10.1016/j.bbmt.2014.04.029. Epub 2014 May 2.

6.

Visceral fat is associated with lower executive functioning in adolescents.

Schwartz DH, Leonard G, Perron M, Richer L, Syme C, Veillette S, Pausova Z, Paus T.

Int J Obes (Lond). 2013 Oct;37(10):1336-43. doi: 10.1038/ijo.2013.104. Epub 2013 Jun 5.

7.

Prenatal exposure to maternal cigarette smoking, amygdala volume, and fat intake in adolescence.

Haghighi A, Schwartz DH, Abrahamowicz M, Leonard GT, Perron M, Richer L, Veillette S, Gaudet D, Paus T, Pausova Z.

JAMA Psychiatry. 2013 Jan;70(1):98-105. doi: 10.1001/archgenpsychiatry.2012.1101.

PMID:
22945562
8.

The role of ovarian steroid hormones in mood.

Schwartz DH, Romans SE, Meiyappan S, De Souza MJ, Einstein G.

Horm Behav. 2012 Sep;62(4):448-54. doi: 10.1016/j.yhbeh.2012.08.001. Epub 2012 Aug 8.

PMID:
22902271
9.

Acquisition of CD4-dependence by CD4-independent SIV passaged in human peripheral blood mononuclear cells.

Iyengar S, Schwartz DH.

Retrovirology. 2012 Jul 25;9:61. doi: 10.1186/1742-4690-9-61.

10.

Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.

Iyengar S, Schwartz DH.

AIDS Res Hum Retroviruses. 2011 May;27(5):519-23. doi: 10.1089/aid.2010.0131. Epub 2010 Nov 23.

11.

Toward genetic rationalization of antiretroviral therapy for HIV.

Schwartz DH, Iyengar S.

AIDS. 2005 Jun 10;19(9):975-7. No abstract available.

PMID:
15905680
12.

How do cell-free HIV virions avoid infecting dead-end host cells and cell fragments?

Lyengar S, Schwartz DH.

AIDS Rev. 2004 Jul-Sep;6(3):155-60. Review.

PMID:
15595432
13.

Modeling partially effective HIV vaccines in vitro.

John R, Arango-Jaramillo S, Self S, Schwartz DH.

J Infect Dis. 2004 Feb 15;189(4):616-23. Epub 2004 Feb 4.

PMID:
14767814
14.

Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5.

John R, Arango-Jaramillo S, Finny GJ, Schwartz DH.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):1-8.

PMID:
14707786
15.

Anatomical loci of HIV-associated immune activation and association with viraemia.

Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH.

Lancet. 2003 Sep 20;362(9388):945-50.

PMID:
14511927
16.

HIV-2 subtype circulating in India (south).

Kannangai R, Shaji RV, Ramalingam S, Jesudason MV, Abraham OC, George R, Shanmugam AP, Schwartz DH, Sridharan G.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):219-22.

PMID:
12794558
17.

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P; AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61.

PMID:
11873074
18.

A peptide enzyme linked immunosorbent assay (ELISA) for the detection of human immunodeficiency virus type-2 (HIV-2) antibodies: an evaluation on polymerase chain reaction (PCR) confirmed samples.

Kannangai R, Ramalingam S, Prakash KJ, Abraham OC, George R, Castillo RC, Schwartz DH, Jesudason MV, Sridharan G.

J Clin Virol. 2001 Aug;22(1):41-6.

PMID:
11418351
19.

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35.

PMID:
11153085
20.

Molecular confirmation of human immunodeficiency virus (HIV) type 2 in HIV-seropositive subjects in south India.

Kannangai R, Ramalingam S, Prakash KJ, Abraham OC, George R, Castillo RC, Schwartz DH, Jesudason MV, Sridharan G.

Clin Diagn Lab Immunol. 2000 Nov;7(6):987-9.

21.

Rapid communication: development of in vitro resistance to macrophage-tropic- and T-cell-line-adapted HIV-1 strains among HIV-positive volunteers treated with highly active antiretroviral therapy.

Castillo RC, Arango-Jaramillo S, John R, Turner BC, Zimmerman E, Schwartz DH.

J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):197-202.

PMID:
10969342
22.

CD4-independent, CCR5-dependent simian immunodeficiency virus infection and chemotaxis of human cells.

Iyengar S, Schwartz DH, Clements JE, Hildreth JE.

J Virol. 2000 Aug;74(15):6720-4.

23.

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.

Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, Schwartz DH.

J Infect Dis. 2000 Mar;181(3):897-903.

PMID:
10720510
24.

Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India.

Srikanth P, Castillo RC, Sridharan G, John TJ, Zachariah A, Mathai D, Schwartz DH.

Int J STD AIDS. 2000 Jan;11(1):49-51.

PMID:
10667901
25.

HIV-2 status in southern India.

Kannangai R, Ramalingam S, Castillo RC, Babu PG, John TJ, Sridharan G, Schwartz DH.

Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):30-1. No abstract available.

PMID:
10492784
26.
27.

A novel factor produced by placental cells with activity against HIV-1.

Sharma UK, Trujillo J, Song HF, Saitta FP, Laeyendecker OB, Castillo R, Arango-Jaramillo S, Sridharan G, Dettenhofer M, Blakemore K, Yu XF, Schwartz DH.

J Immunol. 1998 Dec 1;161(11):6406-12.

28.

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31. Review.

PMID:
9814961
29.

Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages.

Davis BR, Saitta FP, Bauer G, Bunnell BA, Morgan RA, Schwartz DH.

Hum Gene Ther. 1998 May 20;9(8):1197-207.

PMID:
9625259
30.
31.

Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy.

Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, Corey L, Fauci AS.

Nat Med. 1998 Mar;4(3):341-5.

PMID:
9500610
32.

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE.

J Infect Dis. 1998 Feb;177(2):310-9.

PMID:
9466516
33.

Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons.

Schwartz DH, Castillo RC, Arango-Jaramillo S, Sharma UK, Song HF, Sridharan G.

J Infect Dis. 1997 Nov;176(5):1168-74.

PMID:
9359715
34.

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P.

AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77.

PMID:
9310283
35.

Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH.

J Infect Dis. 1997 Aug;176(2):384-97.

PMID:
9237703
36.

Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.

Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, Castillo RC, Reynolds MJ.

Lancet. 1997 Jul 26;350(9073):256-9.

PMID:
9242803
38.

Diagnosis of human immunodeficiency virus infection using citrated whole blood.

Sharma UK, Song HF, Willingham FF, Hannig J, Flexner C, Farzadegan H, Nicolau C, Schwartz DH.

Clin Diagn Lab Immunol. 1997 May;4(3):261-3.

39.

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ.

J Immunol. 1997 Apr 1;158(7):3511-20.

PMID:
9120313
41.

Failure of insulin-like growth factor type I to suppress HIV type 1 in adult or umbilical cord mononuclear blood cells.

Sharma UK, Song H, Casella SJ, Schwartz DH.

AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):105-10.

PMID:
8989433
42.

Selective transmission of human immunodeficiency virus type 1 variants to SCID mice reconstituted with human peripheral blood monoclonal cells.

Markham RB, Schwartz DH, Templeton A, Margolick JB, Farzadegan H, Vlahov D, Yu XF.

J Virol. 1996 Oct;70(10):6947-54.

43.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

Ann Intern Med. 1996 Aug 15;125(4):270-9.

PMID:
8678389
44.

Predominance of defective proviral sequences in an HIV + long-term non-progressor.

Schwartz DH, Viscidi R, Laeyendecker O, Song H, Ray SC, Michael N.

Immunol Lett. 1996 Jun;51(1-2):3-6.

PMID:
8811337
45.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS.

J Infect Dis. 1996 Feb;173(2):340-8.

PMID:
8568294
46.

Early treatment of HIV infection.

Schwartz DH.

N Engl J Med. 1995 Dec 28;333(26):1782; author reply 1783. No abstract available.

PMID:
7491154
47.

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.

Perales MA, Schwartz DH, Fabry JA, Lieberman J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35.

PMID:
7648281
48.

Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus.

Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH.

J Virol. 1995 Jul;69(7):4228-36.

50.

Adherence of human immunodeficiency virus-infected lymphocytes to fetal placental cells: a model of maternal --> fetal transmission.

Schwartz DH, Sharma UK, Perlman EJ, Blakemore K.

Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):978-82.

Supplemental Content

Loading ...
Support Center